Introduction: emerging therapies derived from the molecular pathogenesis of secondary hyperparathyroidism in ESRD patients.
Quarles
L Darryl
LD
D002118:Calcium / Q000502:physiology; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000503:physiopathology; D018167:Receptors, Calcitriol / Q000502:physiology; D018016:Receptors, Parathyroid Hormone / Q000502:physiology
D018167:Receptors, Calcitriol; D018016:Receptors, Parathyroid Hormone; D002118:Calcium